Researchers observed that only 8.3% of 24 children or adolescents with peanut allergy passed a double-blind placebo-controlled food challenge with at least 444 mg of peanut protein after receiving ...

Following receipt of dupilumab for 24 weeks, desensitization to peanut exposure in most children/adolescents with peanut ...

Medscape Medical News, May 16, 2019 Alert European Commission OKs Dupilumab for Severe Asthma Dupilumab is for patients with moderate-to-severe asthma and increased blood eosinophil and/or raised ...

Dupixent (dupilumab) is a brand-name injection that’s prescribed for treating asthma. This article covers topics such as side effects, dosage, and how Dupixent works. Dupixent is available as a ...

Patients with atopic dermatitis using dupilumab vs conventional drugs had less risk for psychiatric and sleep disorders.

18 months after saying "no" to regular NHS funding for Sanofi and Regeneron's Dupixent (dupilumab) for severe asthma in initial guidance, NICE has now backed the drug. The final appraisal ...

such as asthma, allergic rhinitis or food allergies. Dupilumab had previously been shown to be effective in the treatment of atopic dermatitis, but this research is the first to examine the drug's ...

The committee concluded that dupilumab does not represent a cost-effective use of resources, so could not be recommended for treating severe asthma with type 2 inflammation.

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

Initially developed for atopic dermatitis, Enveda's lead asset ENV-294 is now showing promise in treating asthma.

Further information NICE will not progress with an appraisal for this indication due to positive guidance in the adult population within TA751. NHS England and Improvement will commission treatments ...

such as asthma, allergic rhinitis or food allergies. Dupilumab had previously been shown to be effective in the treatment of atopic dermatitis, but this research is the first to examine the drug's ...